FDA warned Zhoushan Haichang over seafood safety plan failures for frozen cut swimming crab, citing sulfite labeling and allergen hazards.
What happened
FDA inspected Zhoushan Haichang’s seafood processing facility in China on March 3 and 4, 2022. FDA found serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) rule: the frozen cut swimming crab plan lacked a labeling critical control point for sulfites, did not list crustacean allergens, and the firm did not adequately monitor water safety, with debris and residue in water used to produce ice. FDA acknowledged the firm’s March 22, 2022, response to the Form 483 inspection observations.
What FDA found
The company’s HACCP plan for frozen cut swimming crab did not include labeling as a critical control point to control sulfites and allowed sulfite residues up to a redacted level without that labeling control.
21 CFR 123.6(a) and (c)(2)The HACCP plan did not list crustacean allergens as a food safety hazard for the frozen cut swimming crab.
21 CFR 123.6(a) and (c)(1)The company did not monitor water safety with enough frequency; FDA found debris and residue in water used to produce ice.
21 CFR 123.11(b)(1)
What FDA wants
FDA asks the company to respond in writing within 15 working days with corrective steps, a revised HACCP plan, and five consecutive days of completed monitoring records for five production date codes, or explain any delay and when it will finish.
Who should pay attention
- US importers and brands sourcing frozen swimming crab from China
- distributors and retailers selling imported frozen seafood
- seafood processors with HACCP and allergen labeling programs
This is a summary. Read the original letter on fda.gov.